Your browser doesn't support javascript.
loading
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Venter, Willem D F; Moorhouse, Michelle; Sokhela, Simiso; Serenata, Celicia; Akpomiemie, Godspower; Qavi, Ambar; Mashabane, Nonkululeko; Arulappan, Natasha; Sim, Joel W; Sinxadi, Phumla Z; Wiesner, Lubbe; Maharaj, Ellisha; Wallis, Carole; Boyles, Tom; Ripin, David; Stacey, Sarah; Chitauri, Gila; Hill, Andrew.
Afiliação
  • Venter WDF; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: fventer@wrhi.ac.za.
  • Moorhouse M; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Sokhela S; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Serenata C; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Akpomiemie G; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Qavi A; Faculty of Medicine, Imperial College London, London, UK.
  • Mashabane N; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Arulappan N; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Sim JW; Faculty of Medicine, Imperial College London, London, UK.
  • Sinxadi PZ; Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Wiesner L; Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Maharaj E; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Wallis C; BARC, Lancet Laboratories, Johannesburg, South Africa.
  • Boyles T; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Ripin D; Clinton Health Access Initiative, Boston, MA, USA.
  • Stacey S; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Division of Infectious Diseases, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.
  • Chitauri G; Division of Infectious Diseases, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.
  • Hill A; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Lancet HIV ; 6(7): e428-e437, 2019 07.
Article em En | MEDLINE | ID: mdl-31202690
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Carga Viral / Terapia Antirretroviral de Alta Atividade Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Fármacos Anti-HIV / Carga Viral / Terapia Antirretroviral de Alta Atividade Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article